Journal
VACCINE
Volume 26, Issue 19, Pages 2335-2343Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2008.02.064
Keywords
EHV-1; canine influenza; H3
Categories
Funding
- NIAID NIH HHS [R21 AI061412-02, R21 AI061412, 5R21AI061412] Funding Source: Medline
- NIGMS NIH HHS [R01 GM080533, R01GM080533] Funding Source: Medline
Ask authors/readers for more resources
In 2004, canine influenza virus (CIV) was identified as a respiratory pathogen of dogs for the first time and found to be closely related to H3N8 equine influenza virus (EIV). We generated a recombinant vectored vaccine that expresses H3 of a recent isolate of EIV using equine herpesvirus type 1 (EHV-1) as the delivery vehicle. This EHV-1 vectored vaccine exhibited robust and stable EIV H3 expression and induced a strong influenza virus-specific response in both mice and dogs upon intranasal. or subcutaneous administration. Furthermore, upon challenge with the recent CIV isolate A/canine/PA/10915-07, protection of vaccinated dogs could be demonstrated by a significant reduction in clinical. sings, and, more importantly, by a significant reduction in virus shedding. We concluded that the EHV-1/H3 recombinant vector can be a valuable alternative for protection of dogs against clinical. disease induced by CIV and can significantly reduce virus spread. (C) 2008 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available